This weekly update in vaccines and immunotherapy covers recent developments across clinical research, regulatory decisions, and real-world effectiveness studies.
In Today’s Newsletter
Dive deeper
💉 RSV + shingles vaccine co-administration [1] [US/Canada • 01 May 2026]
https://www.cidrap.umn.edu/respiratory-syncytial-virus-rsv/giving-rsv-shingles-vaccines-together-appears-safe-older-adults
Context: Randomized, open-label Phase 3 trial in 530 adults aged 50+ in the US and Canada.
Key point: Co-administered RSVPreF3 and recombinant zoster vaccine had non-inferior immune responses versus separate dosing.
Implication: May expand screening, initiation, and follow-up at scale.
🧬 SurVaxM Phase 2 NET trial opens [2] [US • 05 May 2026]
https://www.mimivax.com/mimivax-and-roswell-park-open-phase-2-trial-of-survaxm-for-patients-with-metastatic-neuroendocrine-tumors/
Context: MimiVax and Roswell Park opened Phase 2 trial NCT06202066 in progressing metastatic NETs.
Key point: SurVaxM plus temozolomide will be compared with temozolomide alone for safety and effect.
Implication: Signals pipeline investment and modality expansion.
🦠 Centivax universal flu trial fully enrolls [3] [Australia • 05 May 2026]
https://www.synbiobeta.com/read/centivax-fully-enrolls-180-subject-universal-flu-vaccine-trial-two-months-after-first-dose
Context: First-in-human randomized, double-blind, placebo-controlled Phase 1a trial of Centi-Flu 01.
Key point: Centivax fully enrolled 180 participants and will assess immunogenicity against a 24-strain influenza panel.
Implication: May influence prescriber choice and payer reviews pending full data.
🏭 BioNTech exits COVID vaccine production [4] [Germany • 05 May 2026]
https://www.dw.com/en/germany-biontech-shutting-down-covid-vaccine-production-entirely-1860-jobs-at-risk/a-77055320 Context: BioNTech is closing or winding down facilities in Germany, Singapore, and former CureVac sites. Key point: BioNTech will halt COVID vaccine production and leave manufacturing to Pfizer, citing lower demand. Implication: Signals pipeline investment and modality expansion.
📈 Novavax revenue beat on vaccine deals [5] [US • 06 May 2026]
https://www.reuters.com/business/healthcare-pharmaceuticals/novavax-beats-first-quarter-revenue-estimates-vaccine-deals-strength-2026-05-06/ Context: Novavax reported Q1 revenue of $139.5 million versus analyst estimates of $78.3 million. Key point: Vaccine supply, licensing deals, and Matrix-M partnerships helped offset weaker COVID vaccine demand. Implication: Signals pipeline investment and modality expansion.
📄 Moderna flu vaccine Phase 3 data in NEJM [6] [US/EU/Canada/Australia • 07 May 2026]
https://feeds.issuerdirect.com/news-release.html?newsid=5942413527743400&symbol=MRNA
Context: NEJM published pivotal Phase 3 P304 data for mRNA-1010 in adults aged 50+.
Key point: Moderna reported superior relative vaccine efficacy versus a licensed standard-dose seasonal flu vaccine.
Implication: May influence prescriber choice and payer reviews pending full data.
Why it matters
- Vaccine developers are emphasizing co-administration, broader strain coverage, and differentiated immune platforms.
- COVID vaccine demand pressure is reshaping strategy at BioNTech, Novavax, and Moderna.
- Oncology vaccine programs remain active, with SurVaxM expanding beyond glioblastoma into NETs.
- Regulatory and payer decisions may hinge on full datasets, study design, and comparative performance.
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🎬 Watch on YouTube. Subscribe and never miss a video.
🧰 See our full range of services. Discover how we can help you.
📚 View the full Vaccines archive on our research hub page.
FAQ
What did the RSVPreF3 and shingles vaccine study show?
The Phase 3 trial found that same-day RSVPreF3 and recombinant zoster vaccination did not blunt immune responses versus separate dosing. No vaccine-linked fatal serious adverse events were reported. [1]
What is SurVaxM being tested for in the new MimiVax and Roswell Park trial?
SurVaxM is being tested with temozolomide in progressing metastatic neuroendocrine tumors. The study compares the combination with temozolomide alone. [2]
What makes Centi-Flu 01 different from seasonal flu vaccines?
Centi-Flu 01 is designed to target conserved influenza regions shared across strains. The Phase 1a trial will test immune responses against a 24-strain panel. [3]
Why is BioNTech winding down COVID vaccine production?
BioNTech cited lower COVID vaccine demand and is shifting toward research, including oncology programs such as Pumitamig. Pfizer will handle COVID vaccine production going forward. [4]
What drove Novavax’s Q1 revenue beat?
Novavax reported revenue above analyst estimates, supported by vaccine supply and licensing deals, including Matrix-M adjuvant licensing activity. [5]
What is the status of Moderna’s mRNA-1010 flu vaccine?
mRNA-1010 has Phase 3 data published in NEJM, and regulatory filings are under review in the US, Europe, Canada, and Australia. The FDA PDUFA goal date is 05 Aug 2026. [6]
Entities / Keywords
GSK, RSVPreF3, Arexvy, recombinant zoster vaccine, RZV, Shingrix, RSV, shingles
MimiVax, Roswell Park Comprehensive Cancer Center, SurVaxM, temozolomide, neuroendocrine tumors, NETs, survivin
Centivax, Centi-Flu 01, universal flu vaccine, pan-influenza vaccine, conserved epitopes
BioNTech, Pfizer, COVID vaccine, mRNA vaccine, CureVac, Pumitamig, oncology
Novavax, Matrix-M, Pfizer, Sanofi, vaccine licensing, adjuvant
Moderna, mRNA-1010, seasonal influenza vaccine, NEJM, Phase 3 P304, FDA, PDUFA
References